St. Thomas Hospital ·
Area of research
Epidemiology · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Diabetes, Cardiovascular Risks, and Lipoproteins, Diet, Metabolism, and Disease, and Liver Disease and Transplantation.
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective
Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990–2021
Global Burden of Major Chronic Liver Diseases in 2021
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD
Association between longitudinal weight change and clinical outcome in individuals with MASLD
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
Liver fibrosis progression analyzed with AI predicts renal decline
Associations between skeletal muscle strength and chronic kidney disease in patients with MASLD
Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
MAFLD as part of systemic metabolic dysregulation
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
Bioactive metabolites: A clue to the link between MASLD and CKD?
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease
Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis